Busulfan, Fludarabine, and Alemtuzumab As a Reduced Toxicity Regimen for Children with Malignant and Nonmalignant Diseases Improves Engraftment and Graft-versus-Host Disease without Delaying Immune Reconstitution

Authors:
  • MCMorton J. Cowan
    Morton J. Cowan
  • LMLisa Musick
    Lisa Musick
  • JLJanel R. Long-Boyle
    Janel R. Long-Boyle
  • LBLee Ann Baxter-Lowe
    Lee Ann Baxter-Lowe
  • BHBiljana Horn
    Biljana Horn

Abstract
No abstract available
Keywords

This publication has 19 references indexed in Scilit: